Table 12.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Lung Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	836	948	893	922	977	1,083	1,054	1,099	1,185	1,409
With Immunosuppression Info	764	931	885	895	950	1,065	1,030	1,088	1,163	1,360
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	22.6%	19.5%	13.9%	12.6%	11.9%	8.8%	6.4%	4.9%	5.4%	3.8%
OKT3	3.7%	2.5%	3.5%	3.4%	2.6%	1.0%	0.6%	1.1%	0.5%	0.9%
Thymoglobulin	0.0%	0.0%	0.0%	1.9%	6.0%	5.4%	8.3%	3.0%	3.7%	3.0%
Zenapax	0.0%	0.0%	4.9%	9.6%	14.6%	11.3%	13.7%	15.6%	14.7%	12.1%
Simulect	0.0%	0.0%	0.3%	3.2%	8.3%	12.8%	15.0%	19.6%	23.0%	18.3%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	3.6%	5.2%
No Induction Drugs Recorded	73.8%	78.2%	77.5%	69.5%	56.9%	61.1%	56.3%	55.9%	50.0%	57.4%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.